logo-loader
viewAIM ImmunoTech Inc.

Full interview: Hemispherx Biopharma releases 'well tolerated' data for Ampligen ovarian cancer treatment

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated."

Equels explains the optimal way to administer Ampligen in ovarian cancer patients is into the intraperitoneal cavity near the tumor site, which has been done, and the company has moved forward with Phase II studies.

Quick facts: AIM ImmunoTech Inc.

Price: 2.41 USD

NYSE:AIM
Market: NYSE
Market Cap: $78.62 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to...

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China. Equels telling Proactive how this drug will try to be a...

on 3/3/20

2 min read